Zolmitriptan
- Generic Name
- Zolmitriptan
- Brand Names
- Zomig
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21N3O2
- CAS Number
- 139264-17-8
- Unique Ingredient Identifier
- 2FS66TH3YW
- Background
Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT) receptor agonists used to treat acute migraine. Sumatriptan was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan,...
- Indication
Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.
- Associated Conditions
- Cluster Headache, Migraine
- Associated Therapies
- -
Cocaine and Zolmitriptan
- Conditions
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- William Stoops
- Target Recruit Count
- 20
- Registration Number
- NCT05019430
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Pamukkale University
- Target Recruit Count
- 200
- Registration Number
- NCT03145467
- Locations
- 🇹🇷
Pamukkale University, Denizli, Turkey
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT02609945
- Locations
- 🇺🇸
Site 002, Dallas, Texas, United States
🇺🇸Site 001, Daytona Beach, Florida, United States
Zomig - Treatment of Acute Migraine Headache in Adolescents
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1653
- Registration Number
- NCT01211145
- Locations
- 🇸🇰
Research Site, Zvolen, Slovakia
ZAP, US. Zomig for Appropriate for Primary Care
- Conditions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00637286
Efficacy and Tolerability of Zolmitriptan Nasal Spray
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2114
- Registration Number
- NCT00617747
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT00617695
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.